Monitor enrollment updates for the SOLARA Phase 3 trial and initial Phase 1 data for HMB-003 expected in mid-2027. Data presentations at ASH in December 2026 and EAHAD in February 2027 could provide catalysts.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $38.77entry
- T+1 · 6d ago +1.44%α +0.13% · $39.33
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Hemab Therapeutics reported a Q3 2026 net loss of $27.3M ($0.58 per share), wider than the $17.1M loss in Q3 2025, driven by increased R&D spending as clinical programs advanced. The company initiated a pivotal Phase 3 trial (SOLARA) for sutacimig in Glanzmann thrombasthenia and dosed the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding. Cash of $430.2M is expected to fund operations into 2029.
Key Financial Metrics
Key Facts
- Net loss of $27.3M ($0.58 per share) for Q3 2026, vs $17.1M ($18.04 per share) in Q3 2025
- Cash, cash equivalents and marketable securities totaled $430.2M as of Sep 30, 2026, down from $457.5M as of Jun 30, 2026
- Initiated SOLARA, a pivotal Phase 3 trial of sutacimig in Glanzmann thrombasthenia (GT), the first pivotal trial of a subcutaneous prophylactic treatment in GT
- Dosed first participant in Phase 1 trial of HMB-003 for heavy menstrual bleeding
- First clinical data for sutacimig in Factor VII deficiency showed >50% shortening of prothrombin time in both participants
- R&D expenses were $24.6M in Q3 2026, up from $14.6M in Q3 2025
- G&A expenses were $5.1M in Q3 2026, up from $2.5M in Q3 2025
Financial Impact
Net loss increased by $10.2M YoY; cash burn of $27.3M in the quarter; cash runway into 2029
Risk Factors
- FDA recommended a randomized controlled design for SOLARA; single-arm design may complicate regulatory approval
- No approved prophylactic treatments for GT; trial design and enrollment challenges in rare disease
- Increasing operating losses and cash burn rate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399342 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers